Introduction {#Sec1}
============

It is currently estimated that 415 million people worldwide, approximately 8.8% of all adults, are affected by type 2 diabetes mellitus (T2DM) \[[@CR1]\]. The prevalence of T2DM is highest in older adults \[[@CR2], [@CR3]\]. In the US, from 2001 to 2010, the percentage of people 65--74 years of age with diabetes increased from 9.1% to 20.7% (a 127% increase) and of those 75 years or older from 8.9% to 20.1% (a 126% increase) \[[@CR4]\]. T2DM not only disproportionately affects a large and heterogeneous older patient population, but it is also associated with a variety of complications, including macrovascular (cardiovascular) and microvascular (retinopathy, nephropathy, neuropathy) complications, as well as other conditions such as depression \[[@CR5]\]. In addition, older adults with diabetes are more likely to have a variety of geriatric syndromes and conditions distinct from younger patients with diabetes, including polypharmacy, cognitive impairment, injurious falls, and persistent pain \[[@CR2], [@CR5]\].

A variety of treatment options are available for patients with T2DM, including metformin, sulfonylureas, PPAR-gamma activators, alpha-glucosidase inhibitors, insulin, dipeptidyl peptidase 4 inhibitors (DPP-4i), glucagon-like peptide 1 receptor agonists, and sodium-glucose-linked transport-2 inhibitors \[[@CR6]\]. A physician's choice of treatment for a given patient is often based on the patient's medical condition (severity and duration of T2DM, presence of diabetic complications, other comorbidities, and/or propensity for hypoglycemia) as well as the efficacy and safety profiles of available treatments. Treatment choice can be influenced by physician experience, treatment guidelines, patient preference, formulary access and/or restrictions, and medication cost. Differences in baseline demographic and clinical characteristics among patients initiating different therapies can create systematic differences between treatment groups in clinical practice (i.e., channeling \[[@CR7]\]), which may introduce bias in observational studies.

Sitagliptin, approved in 2006 in the US, was the first available DPP-4 inhibitor \[[@CR8]\]. The efficacy and safety of sitagliptin have been evaluated with an extensive clinical trial program \[[@CR9]--[@CR12]\]. Previous analyses of sitagliptin-prescribing patterns concluded that new users of sitagliptin were more likely to be older and have more comorbidities and complications, greater use of prescription medications, and more physician visits compared to new users of other oral antihyperglycemic agents (OAHAs) \[[@CR13]--[@CR16]\]. However, some studies \[[@CR13], [@CR16]\] used databases that were limited to people carrying commercial insurance and significantly underestimated elderly patients who became eligible for Medicare coverage at 65 years of age. Zhang et al. \[[@CR14]\] assessed the relationship of baseline characteristics and medication use in patients with T2DM who were prescribed sitagliptin vs. other oral antihyperglycemic agents using the GE Healthcare's EMR database. However, this study focused on the general population and did not analyze treatment patterns in older subjects (≥ 65 years of age). As such, we sought to compare the baseline characteristics of elderly patients with T2DM initiating sitagliptin vs. non-DPP-4i OAHAs in the Medicare Supplemental Database.

Methods {#Sec2}
=======

Data Source and Subjects {#Sec3}
------------------------

This study used information from the Truven MarketScan^®^ Medicare Supplemental Database (MarketScan^®^, Truven Health Analytics, Ann Arbor, MI, USA). The database contains the healthcare experience of retirees with Medicare supplemental insurance paid by employers. It also includes the portion of the claim paid by Medicare (represented as "Coordination of Benefits Amount," or COB) in addition to the portions paid by the employer-sponsored supplemental plan and the patient. During 2006--2011, the Medicare Supplemental Database included an average of 2.9 million such patients annually and included information on demographics, health plan membership, medical claims, and pharmacy claims.

Patients ≥ 65 years of age with T2DM were identified if records for the patient indicated at least one inpatient or outpatient diagnosis of diabetes and at least one prescription for OAHA medication. Patients diagnosed with type 1 diabetes, ketoacidosis, malnutrition-associated diabetes, drug-induced diabetes, or gestational diabetes without a subsequent T2DM diagnosis code were excluded from the analysis. Patients on injectable diabetes medications were also excluded.

The time period evaluated for this study was 1 January 2006--31 December 2014. Patients were required to have at least 1 year of continuous enrollment in the database prior to initiation/escalation of antihyperglycemic treatment (i.e., index date) to ensure all patients had 365 days of baseline data available before the index date for each group. Patients initiating sitagliptin were compared to patients initiating any other non-DPP-4i OAHA.

Eligible patients were placed in one of the following three categories according to the complexity of their antihyperglycemic treatment: (1) initiating monotherapy (≥ 1 new outpatient prescription record on or after the T2DM diagnosis); (2) escalating to dual combination therapy (≥ 1 new prescription for a 2nd class of OAHA ≥ 90 days after initiating the 1st class, with the prescription for the 1st class overlapping the index date of 2nd class and with a minimum duration of use of the 1st class ≥ 90 days following the initiation of 2nd class); (3) escalating to triple combination therapy (≥ 1 new prescription for a 3rd class ≥ 90 days after the 2nd class, with prescription for 1st and 2nd classes overlapping the index date of 3rd class, and with the minimum duration of use of the 1st and 2nd classes ≥ 90 days following the initiation of 3rd class).

This article is based on previously conducted studies using a Health Insurance Portability and Accountability Act of 1996 (US) (HIPAA)-compliant database and does not involve any new studies of human or animal subjects performed by any of the authors.

Analysis {#Sec4}
--------

Within each category of OAHA use described above, comparison between sitagliptin and non-DPP-4i OAHA was made across three different age groups: 65--74, 75--84, and ≥ 85 years.

Gender and comorbidity \[arrhythmia, congestive heart failure, cognitive impairment, fracture, hearing loss, hypertension, hypoglycemia, myocardial infarction, neuropathy, peripheral vascular disease, proteinuria, renal failure, retinopathy, stroke/transient ischemic event, and all eye disease (blindness and vision loss, macular edema, retinopathy, cataracts)\] recorded within the 12 months prior to the index date (defined as date of initiation/escalation of antihyperglycemic treatment) were assessed as baseline characteristics in each group. Baseline comorbidities in the population were identified by the presence of any ICD-9-CM diagnosis code, procedure code, or CPT code indicating existence of the condition during the 1 year baseline period prior to index date.

Differences between sitagliptin and non-DPP-4i OAHA treatment groups were compared using standardized difference \[[@CR17]\]. Standardized difference is the difference of two means or proportions divided by the pooled estimate of the standard deviation. Unlike the traditional *p* value, standardized difference is a measure of difference that is not influenced by large sample sizes and has been demonstrated to be a better measure of covariate balance. A standardized difference of at least 10% was used to indicate a meaningful difference between treatment groups \[[@CR18]\].

Results {#Sec5}
=======

A total of 155,388 patients with T2DM were identified as appropriate for this analysis. Over 52% of patients (52.1%; *n* = 80,929) initiated sitagliptin (*n* = 3234) or a non-DPP-4i OAHA monotherapy (*n* = 77,695), 36.8% (*n* = 57,206) initiated an escalation to dual combination therapy (sitagliptin, *n* = 7652; OAHA, *n* = 49,554), and 11.1% (*n* = 17,253) initiated an escalation to triple combination therapy (sitagliptin, *n* = 4429; OAHA, *n* = 12,824). Patients with T2DM who initiated treatment with sitagliptin tended to be older than those initiating other non-DPP-4 OAHAs (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Age distribution of patients ≥ 65 years of age with type 2 diabetes initiating treatment with sitagliptin or a non-DPP-4i oral antihyperglycemic agent (OAHA)

Standardized differences of baseline characteristics of patients with T2DM up to 1 year before initiating treatment with sitagliptin or a non-DPP-4i OAHA were stratified by age and treatment complexity and are presented in Fig. [2](#Fig2){ref-type="fig"}. The greatest differences between treatment groups were observed in patients initiating monotherapy in all three age groups. Compared to patients initiating monotherapy with non-DPP-4i OAHAs, patients initiating monotherapy with sitagliptin were more likely to have a history of arrhythmia (Fig. [2](#Fig2){ref-type="fig"}a--c), congestive heart failure, peripheral vascular disease, renal failure, and stroke. As treatment complexity advanced to dual combination therapy, the differences were attenuated and mostly observed in the 75--84 and ≥ 85 age groups (Fig. [2](#Fig2){ref-type="fig"}d--f). Compared to non-DPP-4i OAHAs, patients initiating an escalation to dual combination therapy with sitagliptin were more likely to have a history of arrhythmia, congestive heart failure, renal failure, and stroke.Fig. 2Standardized differences of baseline characteristics of patients with type 2 diabetes up to 1 year before initiating treatment with sitagliptin or a non-DPP-4i oral antihyperglycemic agent: stratified by treatment complexity and age. *ARR* arrhythmia, *CHF* congestive heart failure, *COG* cognition impairment, *HL* hearing loss, HP hypertension, *MI* myocardial infarction, *Neuro* neuropathy, *ProU* proteinuria, *PVD* peripheral vascular disease, *RF* renal failure, and *STK* stroke

In patients initiating an escalation to triple combination therapy, the differences between treatment groups were not as pronounced as those seen in patients initiating monotherapy or escalation to dual therapy (Fig. [2](#Fig2){ref-type="fig"}g--i). In patients aged 65--74 years initiating triple therapy, all between-group differences were \< 10%.

Discussion {#Sec6}
==========

Patients in observational studies are not randomized with regard to treatment assignment, which may result in an imbalance in one or more important characteristics between treatment groups. This bias, often called confounding by indication, or channeling bias \[[@CR8]\], can affect outcomes of interest and lead to inaccurate conclusions regarding the prescribed treatment.

In this study of patients ≥ 65 years of age with T2DM from the Medicare Supplemental Database, we found that patients with T2DM initiating sitagliptin tend to be older and have more comorbidities than those prescribed other classes of OAHA. These observations of channeling in patients receiving treatment with sitagliptin are similar to those previously reported \[[@CR13], [@CR14], [@CR16]\].

Furthermore, we found that the differences in baseline characteristics between treatment groups vary by age and by the complexity of antihyperglycemic treatment, the latter likely reflecting the limitation of alternative treatment choices with increasing treatment complexity. Patients initiating treatment with sitagliptin were more likely to have a pre-treatment history of arrhythmia, congestive heart failure, peripheral vascular disease, renal failure, and stroke. However, this pattern varied across subgroups defined by age and treatment complexity, with the most pronounced differences observed between patients initiating monotherapy in all three age groups. As treatment complexity advanced to dual combination therapy, the differences were attenuated and mostly observed in the 75--84 and ≥ 85 age groups. In patients aged 65--74 years initiating triple therapy, no meaningful differences were observed between groups.

Features of the US healthcare system are likely influencing the patterns observed in this analysis. Utilization of diabetes medications is influenced by access to healthcare, access to branded therapies, socioeconomic status, insurance coverage, and cost-sharing structure. The study populations were identified in MarketScan^®^ Medicare Supplemental Database, a large, diverse population from the US. However, it contains only Medicare beneficiaries who have employer-sponsored supplemental coverage. As such, these results may not be generalizable to the overall US population or ex-US populations. In addition, the primary uses of these data are for administrative purposes, not research. Consequently, the database has missing or limited data on a number of important disease characteristics and comorbidities, such as duration of diabetes, body weight/body mass index, results of laboratory tests, and adherence to life style modifications.

Conclusion {#Sec7}
==========

This study further documents the presence of channeling in patients initiating treatment with sitagliptin. The analysis reported here suggests important systematic differences between treatment groups are also present in elderly patients initiating OAHA therapy. This should be recognized and addressed appropriately in comparative observational analyses.
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